[{"edinetCode":"E00985","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2382.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":32990000.0,"sharesOwendPercent":0.4401,"outstandingShares":null,"numberOfSubsidiary":8.0,"bps":2146.83,"equityRatio":0.819,"cashAndCashEquivalents":42499000000.0,"assets":192668000000.0,"currentAssets":126267000000.0,"fixedAsset":66400000000.0,"tangibleFixedAssets":22432000000.0,"intangibleFixedAssets":1204000000.0,"investmentAndOtherAssets":42763000000.0,"liabilities":34831000000.0,"currentLiabilities":25033000000.0,"shorTermDept":1321000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":9797000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3630000000.0,"netAsset":157837000000.0,"capitalStock":152585000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":150301000000.0,"treasuryStock":-3168000000.0,"valuationAndConversionAdjustments":5251000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":115373000000.0,"costOfSales":50847000000.0,"grossProfit":64526000000.0,"sgaExpenses":54113000000.0,"salaryAndBenefit":10745000000.0,"depreciationAndSGA":null,"RDExpenses":13569000000.0,"operatingIncome":10413000000.0,"nonOperatingIncome":510000000.0,"nonOperatingExpenses":49000000.0,"interestExpense":29000000.0,"ordinaryProfit":10874000000.0,"extraordinaryGain":48000000.0,"extraordinaryLoss":1205000000.0,"incomeBeforeTax":9716000000.0,"incomeTaxes":2411000000.0,"netIncome":7305000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":7305000000.0,"comprehensiveIncome":5315000000.0,"eps":99.45,"dilutedEps":null,"dividendPerShare":null,"per":23.64,"roe":0.046,"cashFlowFromOperatingActivities":16386000000.0,"depreciationAndCashflowFromOperatingActivities":3619000000.0,"cashFlowFromInvestingActivities":-13142000000.0,"cashFlowFromFinancialActivities":-5721000000.0,"changesInCashAndCashEquivalents":-2543000000.0,"列1":"asr","submitDate":"2017\/6\/26","stockCode":4569,"accountingYear":"第59期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2348.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":33869000.0,"sharesOwendPercent":0.4532,"outstandingShares":null,"numberOfSubsidiary":8.0,"bps":2214.13,"equityRatio":0.823,"cashAndCashEquivalents":42971000000.0,"assets":198350000000.0,"currentAssets":122098000000.0,"fixedAsset":76251000000.0,"tangibleFixedAssets":21901000000.0,"intangibleFixedAssets":1750000000.0,"investmentAndOtherAssets":52600000000.0,"liabilities":35053000000.0,"currentLiabilities":25134000000.0,"shorTermDept":957000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":9918000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3912000000.0,"netAsset":163297000000.0,"capitalStock":155489000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":152542000000.0,"treasuryStock":-2506000000.0,"valuationAndConversionAdjustments":7808000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":110640000000.0,"costOfSales":49064000000.0,"grossProfit":61576000000.0,"sgaExpenses":52753000000.0,"salaryAndBenefit":10449000000.0,"depreciationAndSGA":null,"RDExpenses":14243000000.0,"operatingIncome":8822000000.0,"nonOperatingIncome":640000000.0,"nonOperatingExpenses":118000000.0,"interestExpense":24000000.0,"ordinaryProfit":9345000000.0,"extraordinaryGain":627000000.0,"extraordinaryLoss":910000000.0,"incomeBeforeTax":9061000000.0,"incomeTaxes":2486000000.0,"netIncome":6574000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6574000000.0,"comprehensiveIncome":9132000000.0,"eps":89.28,"dilutedEps":null,"dividendPerShare":null,"per":22.39,"roe":0.041,"cashFlowFromOperatingActivities":10456000000.0,"depreciationAndCashflowFromOperatingActivities":3644000000.0,"cashFlowFromInvestingActivities":-6038000000.0,"cashFlowFromFinancialActivities":-3735000000.0,"changesInCashAndCashEquivalents":471000000.0,"列1":"asr","submitDate":"2018\/6\/25","stockCode":4569,"accountingYear":"第60期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2297.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":22965000.0,"sharesOwendPercent":0.3949,"outstandingShares":null,"numberOfSubsidiary":7.0,"bps":2154.05,"equityRatio":0.713,"cashAndCashEquivalents":30914000000.0,"assets":173034000000.0,"currentAssets":114904000000.0,"fixedAsset":58130000000.0,"tangibleFixedAssets":21792000000.0,"intangibleFixedAssets":3401000000.0,"investmentAndOtherAssets":32936000000.0,"liabilities":49639000000.0,"currentLiabilities":41480000000.0,"shorTermDept":20932000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8159000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2634000000.0,"netAsset":123395000000.0,"capitalStock":116744000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":128999000000.0,"treasuryStock":-17707000000.0,"valuationAndConversionAdjustments":6651000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":113620000000.0,"costOfSales":56210000000.0,"grossProfit":57409000000.0,"sgaExpenses":48436000000.0,"salaryAndBenefit":10370000000.0,"depreciationAndSGA":null,"RDExpenses":10790000000.0,"operatingIncome":8972000000.0,"nonOperatingIncome":798000000.0,"nonOperatingExpenses":332000000.0,"interestExpense":64000000.0,"ordinaryProfit":9438000000.0,"extraordinaryGain":66000000.0,"extraordinaryLoss":145000000.0,"incomeBeforeTax":9359000000.0,"incomeTaxes":2490000000.0,"netIncome":6869000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6869000000.0,"comprehensiveIncome":5711000000.0,"eps":104.68,"dilutedEps":null,"dividendPerShare":null,"per":20.64,"roe":0.048,"cashFlowFromOperatingActivities":340000000.0,"depreciationAndCashflowFromOperatingActivities":2940000000.0,"cashFlowFromInvestingActivities":14939000000.0,"cashFlowFromFinancialActivities":-27315000000.0,"changesInCashAndCashEquivalents":-12057000000.0,"列1":"asr","submitDate":"2019\/6\/24","stockCode":4569,"accountingYear":"第61期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.714,"cashAndCashEquivalents":null,"assets":168548000000.0,"currentAssets":113409000000.0,"fixedAsset":55139000000.0,"tangibleFixedAssets":21498000000.0,"intangibleFixedAssets":3294000000.0,"investmentAndOtherAssets":30345000000.0,"liabilities":48125000000.0,"currentLiabilities":40658000000.0,"shorTermDept":20799000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7467000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2598000000.0,"netAsset":120423000000.0,"capitalStock":115408000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":127664000000.0,"treasuryStock":-17707000000.0,"valuationAndConversionAdjustments":5014000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":25749000000.0,"costOfSales":12423000000.0,"grossProfit":13326000000.0,"sgaExpenses":11751000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2523000000.0,"operatingIncome":1575000000.0,"nonOperatingIncome":277000000.0,"nonOperatingExpenses":25000000.0,"interestExpense":20000000.0,"ordinaryProfit":1827000000.0,"extraordinaryGain":null,"extraordinaryLoss":0.0,"incomeBeforeTax":1826000000.0,"incomeTaxes":545000000.0,"netIncome":1280000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1280000000.0,"comprehensiveIncome":-355000000.0,"eps":22.36,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4569,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":24469000.0,"sharesOwendPercent":0.4208,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.72,"cashAndCashEquivalents":41790000000.0,"assets":165895000000.0,"currentAssets":111204000000.0,"fixedAsset":54690000000.0,"tangibleFixedAssets":21832000000.0,"intangibleFixedAssets":3212000000.0,"investmentAndOtherAssets":29645000000.0,"liabilities":46379000000.0,"currentLiabilities":39203000000.0,"shorTermDept":20666000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7175000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":2559000000.0,"netAsset":119516000000.0,"capitalStock":114963000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":127217000000.0,"treasuryStock":-17706000000.0,"valuationAndConversionAdjustments":4552000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":48299000000.0,"costOfSales":23750000000.0,"grossProfit":24549000000.0,"sgaExpenses":23765000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":5191000000.0,"operatingIncome":783000000.0,"nonOperatingIncome":351000000.0,"nonOperatingExpenses":59000000.0,"interestExpense":41000000.0,"ordinaryProfit":1076000000.0,"extraordinaryGain":123000000.0,"extraordinaryLoss":21000000.0,"incomeBeforeTax":1178000000.0,"incomeTaxes":344000000.0,"netIncome":834000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":834000000.0,"comprehensiveIncome":-1264000000.0,"eps":14.56,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":14652000000.0,"depreciationAndCashflowFromOperatingActivities":1566000000.0,"cashFlowFromInvestingActivities":-753000000.0,"cashFlowFromFinancialActivities":-2993000000.0,"changesInCashAndCashEquivalents":10876000000.0,"列1":"q2r","submitDate":"2019\/11\/14","stockCode":4569,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.711,"cashAndCashEquivalents":null,"assets":172731000000.0,"currentAssets":116037000000.0,"fixedAsset":56694000000.0,"tangibleFixedAssets":21955000000.0,"intangibleFixedAssets":3172000000.0,"investmentAndOtherAssets":31565000000.0,"liabilities":49932000000.0,"currentLiabilities":31794000000.0,"shorTermDept":10533000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":18137000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12585000000.0,"netAsset":122799000000.0,"capitalStock":116759000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":129013000000.0,"treasuryStock":-17706000000.0,"valuationAndConversionAdjustments":6039000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":78614000000.0,"costOfSales":37500000000.0,"grossProfit":41113000000.0,"sgaExpenses":35841000000.0,"salaryAndBenefit":8274000000.0,"depreciationAndSGA":null,"RDExpenses":7584000000.0,"operatingIncome":5271000000.0,"nonOperatingIncome":663000000.0,"nonOperatingExpenses":99000000.0,"interestExpense":61000000.0,"ordinaryProfit":5836000000.0,"extraordinaryGain":123000000.0,"extraordinaryLoss":24000000.0,"incomeBeforeTax":5935000000.0,"incomeTaxes":1560000000.0,"netIncome":4374000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4374000000.0,"comprehensiveIncome":3762000000.0,"eps":76.36,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/14","stockCode":4569,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2271.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":24328000.0,"sharesOwendPercent":0.4184,"outstandingShares":null,"numberOfSubsidiary":6.0,"bps":2142.07,"equityRatio":0.717,"cashAndCashEquivalents":30509000000.0,"assets":171160000000.0,"currentAssets":117058000000.0,"fixedAsset":54102000000.0,"tangibleFixedAssets":22721000000.0,"intangibleFixedAssets":3332000000.0,"investmentAndOtherAssets":28047000000.0,"liabilities":48449000000.0,"currentLiabilities":31328000000.0,"shorTermDept":10400000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":17121000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12514000000.0,"netAsset":122710000000.0,"capitalStock":118534000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":130788000000.0,"treasuryStock":-17706000000.0,"valuationAndConversionAdjustments":4176000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":109983000000.0,"costOfSales":52950000000.0,"grossProfit":57032000000.0,"sgaExpenses":49528000000.0,"salaryAndBenefit":10505000000.0,"depreciationAndSGA":null,"RDExpenses":10987000000.0,"operatingIncome":7503000000.0,"nonOperatingIncome":801000000.0,"nonOperatingExpenses":128000000.0,"interestExpense":75000000.0,"ordinaryProfit":8175000000.0,"extraordinaryGain":123000000.0,"extraordinaryLoss":43000000.0,"incomeBeforeTax":8255000000.0,"incomeTaxes":2106000000.0,"netIncome":6149000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6149000000.0,"comprehensiveIncome":3674000000.0,"eps":107.35,"dilutedEps":null,"dividendPerShare":null,"per":20.48,"roe":0.05,"cashFlowFromOperatingActivities":7739000000.0,"depreciationAndCashflowFromOperatingActivities":3221000000.0,"cashFlowFromInvestingActivities":-2943000000.0,"cashFlowFromFinancialActivities":-5117000000.0,"changesInCashAndCashEquivalents":-343000000.0,"列1":"asr","submitDate":"2020\/6\/22","stockCode":4569,"accountingYear":"第62期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.73,"cashAndCashEquivalents":null,"assets":168471000000.0,"currentAssets":112169000000.0,"fixedAsset":56302000000.0,"tangibleFixedAssets":23218000000.0,"intangibleFixedAssets":3365000000.0,"investmentAndOtherAssets":29718000000.0,"liabilities":45505000000.0,"currentLiabilities":28458000000.0,"shorTermDept":10375000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":17047000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":12464000000.0,"netAsset":122965000000.0,"capitalStock":117521000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":129775000000.0,"treasuryStock":-17706000000.0,"valuationAndConversionAdjustments":5444000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":24689000000.0,"costOfSales":11595000000.0,"grossProfit":13094000000.0,"sgaExpenses":11080000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2047000000.0,"operatingIncome":2014000000.0,"nonOperatingIncome":272000000.0,"nonOperatingExpenses":21000000.0,"interestExpense":17000000.0,"ordinaryProfit":2265000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":8000000.0,"incomeBeforeTax":2256000000.0,"incomeTaxes":647000000.0,"netIncome":1609000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1609000000.0,"comprehensiveIncome":2872000000.0,"eps":28.1,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/11","stockCode":4569,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":25938000.0,"sharesOwendPercent":0.446,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.727,"cashAndCashEquivalents":35792000000.0,"assets":169789000000.0,"currentAssets":113860000000.0,"fixedAsset":55929000000.0,"tangibleFixedAssets":23105000000.0,"intangibleFixedAssets":3306000000.0,"investmentAndOtherAssets":29517000000.0,"liabilities":46389000000.0,"currentLiabilities":30812000000.0,"shorTermDept":10478000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":15576000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":11137000000.0,"netAsset":123400000000.0,"capitalStock":118045000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":130284000000.0,"treasuryStock":-17691000000.0,"valuationAndConversionAdjustments":5355000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":47735000000.0,"costOfSales":22913000000.0,"grossProfit":24822000000.0,"sgaExpenses":23320000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":5200000000.0,"operatingIncome":1502000000.0,"nonOperatingIncome":356000000.0,"nonOperatingExpenses":45000000.0,"interestExpense":35000000.0,"ordinaryProfit":1813000000.0,"extraordinaryGain":1074000000.0,"extraordinaryLoss":12000000.0,"incomeBeforeTax":2874000000.0,"incomeTaxes":756000000.0,"netIncome":2118000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2118000000.0,"comprehensiveIncome":3291000000.0,"eps":36.98,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":11300000000.0,"depreciationAndCashflowFromOperatingActivities":1716000000.0,"cashFlowFromInvestingActivities":-3174000000.0,"cashFlowFromFinancialActivities":-2829000000.0,"changesInCashAndCashEquivalents":5282000000.0,"列1":"q2r","submitDate":"2020\/11\/13","stockCode":4569,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.726,"cashAndCashEquivalents":null,"assets":168737000000.0,"currentAssets":116591000000.0,"fixedAsset":52145000000.0,"tangibleFixedAssets":23241000000.0,"intangibleFixedAssets":3787000000.0,"investmentAndOtherAssets":25117000000.0,"liabilities":46285000000.0,"currentLiabilities":30978000000.0,"shorTermDept":10325000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":15306000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":11086000000.0,"netAsset":122452000000.0,"capitalStock":118708000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":130926000000.0,"treasuryStock":-17670000000.0,"valuationAndConversionAdjustments":3743000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":74955000000.0,"costOfSales":36156000000.0,"grossProfit":38798000000.0,"sgaExpenses":34684000000.0,"salaryAndBenefit":7997000000.0,"depreciationAndSGA":null,"RDExpenses":7603000000.0,"operatingIncome":4114000000.0,"nonOperatingIncome":651000000.0,"nonOperatingExpenses":110000000.0,"interestExpense":52000000.0,"ordinaryProfit":4656000000.0,"extraordinaryGain":1441000000.0,"extraordinaryLoss":13000000.0,"incomeBeforeTax":6084000000.0,"incomeTaxes":1579000000.0,"netIncome":4504000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4504000000.0,"comprehensiveIncome":4066000000.0,"eps":78.63,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/15","stockCode":4569,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":2243.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":25553000.0,"sharesOwendPercent":0.4394,"outstandingShares":null,"numberOfSubsidiary":5.0,"bps":2175.52,"equityRatio":0.746,"cashAndCashEquivalents":26476000000.0,"assets":167126000000.0,"currentAssets":114027000000.0,"fixedAsset":53099000000.0,"tangibleFixedAssets":23896000000.0,"intangibleFixedAssets":3785000000.0,"investmentAndOtherAssets":25417000000.0,"liabilities":42464000000.0,"currentLiabilities":27407000000.0,"shorTermDept":10300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":15057000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":11036000000.0,"netAsset":124661000000.0,"capitalStock":120339000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":132557000000.0,"treasuryStock":-17671000000.0,"valuationAndConversionAdjustments":4322000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":102904000000.0,"costOfSales":51276000000.0,"grossProfit":51627000000.0,"sgaExpenses":45841000000.0,"salaryAndBenefit":10087000000.0,"depreciationAndSGA":null,"RDExpenses":9703000000.0,"operatingIncome":5786000000.0,"nonOperatingIncome":798000000.0,"nonOperatingExpenses":137000000.0,"interestExpense":68000000.0,"ordinaryProfit":6447000000.0,"extraordinaryGain":1929000000.0,"extraordinaryLoss":25000000.0,"incomeBeforeTax":8352000000.0,"incomeTaxes":2222000000.0,"netIncome":6130000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6130000000.0,"comprehensiveIncome":6276000000.0,"eps":106.99,"dilutedEps":null,"dividendPerShare":null,"per":18.02,"roe":0.05,"cashFlowFromOperatingActivities":5189000000.0,"depreciationAndCashflowFromOperatingActivities":3564000000.0,"cashFlowFromInvestingActivities":-4259000000.0,"cashFlowFromFinancialActivities":-4918000000.0,"changesInCashAndCashEquivalents":-4033000000.0,"列1":"asr","submitDate":"2021\/6\/21","stockCode":4569,"accountingYear":"第63期（自　2020年４月１日　至　2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.74,"cashAndCashEquivalents":null,"assets":163555000000.0,"currentAssets":111745000000.0,"fixedAsset":51810000000.0,"tangibleFixedAssets":23603000000.0,"intangibleFixedAssets":3598000000.0,"investmentAndOtherAssets":24607000000.0,"liabilities":42474000000.0,"currentLiabilities":27619000000.0,"shorTermDept":10300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14854000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":10986000000.0,"netAsset":121080000000.0,"capitalStock":117260000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":129479000000.0,"treasuryStock":-17671000000.0,"valuationAndConversionAdjustments":3819000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":24695000000.0,"costOfSales":13682000000.0,"grossProfit":11012000000.0,"sgaExpenses":11769000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2120000000.0,"operatingIncome":-756000000.0,"nonOperatingIncome":285000000.0,"nonOperatingExpenses":19000000.0,"interestExpense":17000000.0,"ordinaryProfit":-491000000.0,"extraordinaryGain":null,"extraordinaryLoss":6000000.0,"incomeBeforeTax":-497000000.0,"incomeTaxes":-35000000.0,"netIncome":-462000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-462000000.0,"comprehensiveIncome":-965000000.0,"eps":-8.06,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/10","stockCode":4569,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":26419000.0,"sharesOwendPercent":0.4543,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.742,"cashAndCashEquivalents":31298000000.0,"assets":164408000000.0,"currentAssets":112811000000.0,"fixedAsset":51597000000.0,"tangibleFixedAssets":23198000000.0,"intangibleFixedAssets":3489000000.0,"investmentAndOtherAssets":24908000000.0,"liabilities":42480000000.0,"currentLiabilities":27754000000.0,"shorTermDept":10300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14726000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":10936000000.0,"netAsset":121927000000.0,"capitalStock":117844000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":130062000000.0,"treasuryStock":-17671000000.0,"valuationAndConversionAdjustments":4083000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":49102000000.0,"costOfSales":26732000000.0,"grossProfit":22369000000.0,"sgaExpenses":22438000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4364000000.0,"operatingIncome":-68000000.0,"nonOperatingIncome":402000000.0,"nonOperatingExpenses":48000000.0,"interestExpense":34000000.0,"ordinaryProfit":285000000.0,"extraordinaryGain":null,"extraordinaryLoss":16000000.0,"incomeBeforeTax":269000000.0,"incomeTaxes":147000000.0,"netIncome":121000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":121000000.0,"comprehensiveIncome":-117000000.0,"eps":2.12,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":9432000000.0,"depreciationAndCashflowFromOperatingActivities":1831000000.0,"cashFlowFromInvestingActivities":-1907000000.0,"cashFlowFromFinancialActivities":-2776000000.0,"changesInCashAndCashEquivalents":4822000000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4569,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0},{"edinetCode":"E00985","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.726,"cashAndCashEquivalents":null,"assets":169106000000.0,"currentAssets":116105000000.0,"fixedAsset":53000000000.0,"tangibleFixedAssets":22892000000.0,"intangibleFixedAssets":3323000000.0,"investmentAndOtherAssets":26784000000.0,"liabilities":46253000000.0,"currentLiabilities":31674000000.0,"shorTermDept":10300000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":14579000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":10886000000.0,"netAsset":122853000000.0,"capitalStock":119042000000.0,"capital":700000000.0,"capitalSurplus":4752000000.0,"accumulatedEarnings":131261000000.0,"treasuryStock":-17671000000.0,"valuationAndConversionAdjustments":3810000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":77717000000.0,"costOfSales":41477000000.0,"grossProfit":36240000000.0,"sgaExpenses":33313000000.0,"salaryAndBenefit":7723000000.0,"depreciationAndSGA":null,"RDExpenses":6571000000.0,"operatingIncome":2926000000.0,"nonOperatingIncome":654000000.0,"nonOperatingExpenses":65000000.0,"interestExpense":51000000.0,"ordinaryProfit":3515000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":17000000.0,"incomeBeforeTax":3498000000.0,"incomeTaxes":1015000000.0,"netIncome":2483000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2483000000.0,"comprehensiveIncome":1971000000.0,"eps":43.34,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4569,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00985","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":700,"settlementDate":"2022\/3\/31","submitterName":"キョーリン製薬ホールディングス株式会社","submitterNameEnglish":"KYORIN Holdings,Inc.","submitterNameKana":"キョーリンセイヤクホールディングスカブシキガイシャ","location":"千代田区神田駿河台四丁目６番地","industory":"医薬品","corporateNumber":8010000000000.0}]